Skip to main content
. 2017 Aug 14;4(3):ofx167. doi: 10.1093/ofid/ofx167

Table 4.

Hazard Ratio of Mortality by Tuberculosis Screening Method Among Newly Diagnosed HIV-Infected South African Adults

Screening Test Number of Deaths/ Number at Risk (%) Unadjusted Models Adjusted Modelsa
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
All Participants
 Absence of Cough 46/471 (9.8) Ref. Ref.
 Presence of Cough 43/255 (16.9) 1.80 (1.18–2.72) .006 1.68 (1.10–2.55) .02
 No TB-related symptoms 17/277 (6.1) Ref. Ref.
 Any TB-related symptom 72/449 (16.0) 2.76 (1.63–4.68) .0002 2.41 (1.41–4.12) .001
 Sputum AFB smear-negative 75/650 (11.5) Ref. Ref.
 Sputum AFB smear-positive 6/37 (16.2) 1.43 (062-3.29) .40 1.22 (0.53–2.82) .64
 Urine LAM-negative 60/632 (9.5) Ref. Ref.
 Urine LAM-positive 29/93 (31.2) 3.72 (2.39–5.79) <.0001 3.18 (2.02–5.00) <.0001
 Urine LAM <2+ grade 30/313 (9.6) Ref. Ref.
 Urine LAM ≥2+ grade 14/36 (38.9) 4.74 (2.51–8.95) <.0001 3.34 (1.73–6.46) .0003
Participants With Evidence of TBb
 Absence of Cough 31/90 (34.4) Ref. Ref.
 Presence of Cough 44/85 (51.8) 1.82 (1.14–2.89) .01 1.67 (1.04–2.69) .03
 No TB-related symptoms 16/39 (41.0) Ref. Ref.
 Any TB-related symptom 59/136 (43.4) 1.22 (0.70–2.13) .47 1.07 (0.61–1.88) .82
 Urine LAM-negative 42/124 (33.9) Ref. Ref.
 Urine LAM-positive 33/51 (64.7) 2.51 (1.58–4.00) <.0001 2.48 (1.55–3.98) .0002
Participants With Evidence of TBb and CD4 <200/mm3
 Absence of Cough 25/64 (39.1) Ref. Ref.
 Presence of Cough 36/66 (54.6) 1.63 (0.97–2.73) .06 1.42 (0.83–2.41) .20
 No TB-related symptoms 11/25 (44.0) Ref. Ref.
 Any TB-related symptom 50/105 (47.6) 1.22 (0.64–2.35) .55 1.09 (0.56–2.12) .81
 Urine LAM-negative 33/87 (37.9) Ref. Ref.
 Urine LAM-positive 28/43 (65.1) 2.45 (1.47–4.10) .0006 2.29 (1.35–3.88) .002

Abbreviations: AFB, acid-fast bacilli; CI, confidence interval; HIV, human immunodeficiency virus; LAM, lipoarabinomannan; Ref., ; TB, tuberculosis.

aAdjusted by age, sex, education, and smoking status.

bEvidence of TB was defined as either microbiologically TB+ being empirically stated on anti-TB therapy.